Micafungin: Difference between revisions
(Text replacement - "* " to "*") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antifungal | *Type: [[Antifungal]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: Intravenous | *Routes of Administration: Intravenous | ||
| Line 53: | Line 53: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Revision as of 23:27, 22 September 2019
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration: Intravenous
- Common Trade Names:
Adult Dosing
- Candidiasis or aspergillosis treatment: 50-150mg IV daily
- Antifungal prophylaxis: 1mg/kg IV daily
Pediatric Dosing
- <4mo, <40kg: 2-3mg/kg IV daily
- <4mo, >40kg: 100-150 mg IV daily
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Atrial fibrillation, MI, pericardial effusion, cardiac arrest
- Anemia, hemolysis
- Liver failure, hepatitis
- Encephalopathy
- Intracranial hemorrhage
- Seizure
- Acute renal failure
Common
- Nausea, vomiting, diarrhea
- Headache
- Fever
- Thrombocytopenia
Pharmacology
- Half-life: 5.5-21h
- Metabolism: Hepatic, mostly CYP3A
- Excretion: Mostly fecal
Mechanism of Action
- Inhibits the synthesis of vital fungal cell wall component 1,3 beta-D-glucan